An announcement was made earlier today by the Swiss pharmaceutical company, Helsinn, that new appointments have been made in the membership of the Board of Directors of Helsinn Group under which Lonnie Moulder and Eric Cornut were granted membership in the board and will take hold of their designations immediately.
Eric Cornut has a vast experience of 27 years in the pharmaceutical management and previously had a Board role for over a year, from May’17 to Oct’18 and will now rejoin the Helsinn Group Board. He previously held the role of Interim Director General of The European Federation of Pharmaceutical Industries and Associations (EFPIA) where he served as the chairman of the executive committee of the EFPIA for five years, from 2008 to 2013.
Eric has also experience at Novartis AG, serving at various high-profile designations for over twenty years. His positions included Novartis International AG’s Chief Ethics, Compliance and Policy Officer, and Novartis Pharma AG’s Chief Commercial Officer. Eric currently serves as the Stada AG’s Supervisory Board member and Menarini’s Group Chairman. Eric graduated as a Ph.D. holder in Law degree from the University of Basel, Switzerland and is also a Master Law graduate from the University of California, Berkeley, USA.
Lonnie Moulder has a vast experience of over 30 years in leadership and serves as the Board level advisor. The most recent designation of Lonnie was the CEO of a biopharmaceutical company, Tesaro, Inc. Lonie founded the company himself and in 2019 sold it to GlaxoSmithKline for $5.1 billion. He has also taken the position of MGI PHARMA’s CEO which the Eisai Co., Ltd. Bought for $3.9 billion in 2008. Abraxis BioScience, Inc. has also witnessed Lonnie as one of its CEOs.
Lonnie currently serves as the Tellus BioVentures’ Founding General Partner and participates actively as the Temple University’s Board of Trustees member. Lonnie holds an MBA degree from the University Of Chicago Booth School Of Business.